Incyte (LTS:0J9P) Short-Term Capital Lease Obligation : $8 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Short-Term Capital Lease Obligation?

Incyte's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $8 Mil.

Incyte's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 ($9 Mil) to Dec. 2023 ($9 Mil) and declined from Dec. 2023 ($9 Mil) to Mar. 2024 ($8 Mil).

Incyte's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($13 Mil) to Dec. 2022 ($11 Mil) and declined from Dec. 2022 ($11 Mil) to Dec. 2023 ($9 Mil).

Incyte Short-Term Capital Lease Obligation Historical Data

The historical data trend for Incyte's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Short-Term Capital Lease Obligation Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

10.01

14.96

13.19

11.37

9.13

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															10.54	10.25	9.25	9.13	8.46

Incyte Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Incyte Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Incyte's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (LTS:0J9P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (LTS:0J9P) Headlines

No Headlines